UNION has built a differentiated clinical-stage pipeline with seven clinical programs in immunology and infectious diseases based on four distinct product candidates from two differentiated compound classes that are represented by our lead molecules orismilast and niclosamide. Current priorities include:

Orismilast:

• Three programs with oral orismilast (UNI5001) which has demonstrated proof-of-concept in psoriasis. The target indications are psoriasis, atopic dermatitis and hidradenitis suppurativa
• One program with topical orismilast (UNI50002) which has demonstrated proof-of-concept in atopic dermatitis

Niclosamide:

• Three programs with niclosamide, two of which are a niclosamide nasal spray (UNI91103) targeting COVID-19 prophylaxis and mild COVID-19, and one of which is inhalation-based (UNI91104) and targets moderate COVID-19

Our pipeline also includes topical oxyclozanide for canine pyoderma which has been out-licensed to Ceva.